Table 3 Logistic regression analysis of the various factors associated with the different anti-malarial markers from the study sites
Factors | Pfdhfr | Pfdhps | Pfmdr1 | |||
|---|---|---|---|---|---|---|
n/d (%) | OR (95% CI) | n/d (%) | OR (95% CI) | n/d (%) | OR (95% CI) | |
Endemicity | ||||||
 Low | 12/19 (63.16) | Reference | 17/17 (100) | Reference | 4/11 (36.36) | Reference |
 Moderate | 30/65 (46.15) | 0.50 (0.17–1.43) | 77/77 (100) | Empty | 27/47 (57.45) | 2.26 (0.61–9.18) |
 High | 73/115 (63.48) | 1.10 (0.37–2.77) | 105/121 (86.78) | Omitted | 60/83 (72.29) | 4.56 (1.22–17.07)* |
Age group | ||||||
 Adults | 90/158 (56.96) | Reference | 161/170 (94.71) | Reference | 74/117 (63.25) | Reference |
 Children | 25/41 (60.98) | 1.18 (0.58–2.38) | 38/45 (84.44) | 0.30 (0.11–0.87)* | 17/24 (70.83) | 1.41 (0.54–3.67) |
Symptoms | ||||||
 Symptomatic | 96/166 (57.83) | Reference | 162/177 (91.53) | Reference | 69/105 (65.71) | Reference |
 Asymptomatic | 19/33 (57.58) | 0.98 (0.46–2.11) | 37/38 (97.37) | 3.43 (0.44–26.76) | 22/36 (61.11) | 0.82 (0.37–1.79) |
Year | ||||||
 2019 | 31/64 (48.44) | Reference | 70/74 (94.59) | Reference | 43/68 (63.24) | Reference |
 2020 | 84/135 (62.22) | 1.75 (0.96–3.20) | 129/141 (91.49) | 0.61 (0.19–1.98) | 48/73 (65.75) | 1.12 (0.56–2.23) |